Intra-Cellular Therapies shares phase 3 results for major depressive disorder therapy
Betsy Goodfellow | April 17, 2024 | News story | Research and Development | Intra-Cellular Therapies, Neurology, clinical trial, major depressive disorder, mental health
Intra-Cellular Therapies has announced positive topline results from Study 501, which assessed lumateperone 42mg as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD).
The drug given once daily as an adjunctive therapy to antidepressants met its primary endpoint in the trial, demonstrating a statistically significant and clinically meaningful reduction in the Montogmer-Asberg Depression Rating Scale (MADRS) total score at week 6 when compared to placebo. It also met its secondary endpoint of reduction in Clinical Global Impression Scale for Severity of Illness (CGI-S) at week 6 compared to placebo.
Topline results from the second phase 3 trial, Study 502, are expected in the second quarter of 2024.
Dr Sharon Mates, chairman and chief executive officer of Intra-Cellular Therapies, commented: “The positive phase 3 results in MDD represent a significant step towards our goal of further establishing Caplyta as a first-choice treatment across mood disorders. We believe that these robust efficacy results, coupled with its favourable safety and tolerability profile and convenient dosing, make Caplyta a compelling option as an adjunctive treatment for MDD, if approved. At Intra-Cellular Therapies, we are committed to bringing improved treatment options to patients with major neuropsychiatric conditions through our efforts to expand Caplyta’s label and advance our pipeline.”
Betsy Goodfellow
Related Content
FDA signals support for development of psychedelic therapies in mental healthmental health
The US Food and Drug Administration (FDA) has announced a series of measures aimed at …
Stage4You encourages stage 4 bowel cancer patients to prioritise mental health ahead of Bowel Cancer Awareness Month
Stage4You, a campaign funded and developed by Takeda UK and supported by Bowel Cancer UK, …
Historic UN declaration supporting mental health – treatment to be given similar priority to chronic diseases
The 80th United Nations General Assembly (UNGA) has adopted the political declaration to combat mental …
